A randomized, open-label study of oral Bondronat, intravenous Bondronat, or intravenous zoledronic on pain response in patients with different tumor types
Latest Information Update: 04 Apr 2022
At a glance
- Drugs Ibandronic acid (Primary) ; Zoledronic acid
- Indications Breast cancer; Cancer metastases; Lung cancer; Prostate cancer; Solid tumours
- Focus Therapeutic Use
- Sponsors Roche
- 03 Apr 2022 Status changed from discontinued to completed.
- 19 Apr 2009 Status changed from completed to discontinued as reported by Roche.
- 16 Jul 2008 Status changed from in progress to completed, from Roche record.